## Suppl. figure e-1 Study duration Core study Extension study Follow-up year Year 1 Year 2 Year 3 Year 4 Year 5 Follow-up month 0 12 24 36 48 60 Alemtuzumab 12 mg IV Course 1 Course 2 141 Patients achieved NEDA in Year 2 and Sustained NEDA (4 years) received no retreatment from Months 12-60 No alemtuzumab retreatment No other DMT В 100-No alemtuzumab retreatment or other DMT 80-Sustained Patients with NEDA, **NEDA** 75 75 % (95% CI) 60-67 40-48 20-Year 3 Year 4 Year 5 Years 2-5 (Months 12-60) Extension study No. of patients 134 119 110 108 Free of relapse 95% 94% 94% 84% Free of 6-month CDW 94% 91% 96% 98% Free of clinical disease 90% 78% 91% 92% activity **Gd-enhancing** 94% 97% 93% 89%

Figure e-1 Sustained NEDA outcomes for 4 years in patients who received only the initial 2 courses of alemtuzumab

81%

80%

69%

69%

59%

59%

T, lesion-free

New/enlarging T<sub>2</sub> lesion-free Free of MRI

lesion activity

84%

83%

(A) Schematic for the methodology for describing patients with 4-year sustained NEDA. (B) NEDA outcomes were assessed for patients who received the initial 2 alemtuzumab courses in the core CARE-MS II study, achieved NEDA at Year 2 of the core study, and received no alemtuzumab retreatment since Month 12 or treatment with another DMT through 5 years. Sustained outcomes were calculated cumulatively over Years 2–5. <sup>a</sup>Baseline percentage of patients Gd-enhancing lesion-free: 59%. CDW = confirmed disability worsening; DMT = disease-modifying therapy; Gd = gadolinium; NEDA = no evidence of disease activity.